Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil (Aricept) for cognitive dysfunction in children with Down syndrome
2016-004948-11Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Down syndrome and confusion comparing Donepezil (Aricept) with Placebo (2 arms). Primary endpoint: Primary: Change in VABS-II/PCRF score.
02
Drugs
donepezil
03
Conditions
Down syndromeconfusion
Beyond the preview
Go deeper on 2016-004948-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004948-11.